MedPath

Cefixime

Generic Name
Cefixime
Brand Names
Suprax
Drug Type
Small Molecule
Chemical Formula
C16H15N5O7S2
CAS Number
79350-37-1
Unique Ingredient Identifier
XZ7BG04GJX

Overview

Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

Background

Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

Indication

For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes, (3) pharyngitis and tonsillitis caused by S. pyogenes, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains).

Associated Conditions

  • Acute Exacerbation of Chronic Bronchitis caused by Streptococcus Pneumoniae
  • Acute Exacerbations of Chronic Bronchitis caused by Haemophilus Influenzae
  • Bacterial Sinusitis
  • Community Acquired Pneumonia (CAP)
  • Gonorrhea of anus
  • Lyme Disease
  • Salmonella Infections
  • Shigella Infection
  • Streptococcal Pharyngitis
  • Tonsillitis streptococcal
  • Uncomplicated Urinary Tract Infections
  • Bacterial otitis media
  • Bacterial rhinosinusitis
  • Disease caused by Salmonella typhi
  • Uncomplicated Gonorrhea

FDA Approved Products

Cefixime
Manufacturer:Dr. Reddy’s Laboratories, Inc
Route:ORAL
Strength:100 mg in 5 mL
Approved: 2023/10/05
NDC:43598-673
Cefixime
Manufacturer:Belcher Pharmaceuticals,LLC
Route:ORAL
Strength:200 mg in 5 mL
Approved: 2023/10/09
NDC:62250-664
SUPRAX
Manufacturer:Lupin Pharmaceuticals, Inc.
Route:ORAL
Strength:500 mg in 5 mL
Approved: 2023/12/15
NDC:27437-207
SUPRAX
Manufacturer:Lupin Pharmaceuticals, Inc.
Route:ORAL
Strength:200 mg in 5 mL
Approved: 2023/12/15
NDC:27437-206
Cefixime
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:100 mg in 5 mL
Approved: 2024/02/14
NDC:65862-751

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath